Key TakeawaysMedicare drug price negotiation would be scaled to cover more drugs faster, eliminate “blockbuster” exemptions, add international reference pricing elements, and extend savings beyond Medicare into commercial markets.Recent manufacturer increases across 948 brand-name drugs—including nivolumab, pembrolizumab, and ravulizumab—are leveraged to argue prior actions lacked enforceable cost-lowering mechanisms.Middlemen incentives are framed as a key barrier […]
